NEWS
Intas granted injunction over similar trademark Indian
pharmaceutical company Intas
Pharmaceuticals has been granted an injunction preventing a rival from marketing an anti-epilepsy drug it said infringed one of its trademarks.
According to Ahmedabad-based Intas, the Delhi High Court accepted its request to issue Arinna Lifesciences with an ex parte injunction preventing it from selling its drug Valrope.
Intas claimed the name was too similar to that of its own drug, Valprol (divalproex sodium), which it has marketed since 1991 and is also used to treat epilepsy.
T e court, according to Intas, restrained Arinna from using, advertising, marketing, or selling “in any manner whatsoever” the trademark ‘Valrope’ or any other trademark or name which is “identical and deceptively similar” to Intas’s trademark.
T e court added that Vivek Seth, director of
Arinna, was a former vice president of Intas. “T e chances of
confusion between Intas’s
Valprol and the recently launched Valrope are high,” the court wrote.
T e injunction will be in place pending the outcome of the case.
Intas and Arinna did not respond to a request for comment.
Mylan defeated by The Medicines Company in patent lawsuit
A US court has ruled that pharmaceutical company Mylan infringed a patent owned by T e Medicines Company covering a product used to inhibit blood clots.
T e Medicines Company, based in New Jersey,
had opposed Mylan’s ANDA for a proposed drug that it said infringed its patent for Angiomax (bivalirudin).
In its response, Mylan argued that several of T e Medicines Company’s patent claims, which
centred on US patent number 7,582,727, were invalid.
But, in a decision issued on October 27, the US District Court for Northern District of Illinois Eastern Division rejected Mylan’s claims on the grounds that it failed to provide “clear and convincing” evidence.
In a statement, Clive Meanwell, chairman and chief executive at T e Medicines Company, said it was “highly satisfi ed” with the court’s ruling.
He added that it “supports our ongoing conviction to defend these patents vigorously”.
Mylan’s ANDA sought approval from the US FDA to commercially manufacture, use or sell a generic version of Angiomax before the ‘727 patent expired, in 2028.
T e court’s ruling now prevents Mylan from obtaining FDA approval to produce a generic before the ’727 patent expires in 2028.
Angiomax, an injectable drug, was approved by the FDA in 2000 to be used in conjunction with aspirin for patients undergoing heart surgery.
According to Reuters, Angiomax accounted for 87% of the total revenue reported by T e Medicines Company for the quarter ending September 2014.
Mylan did not respond to a request for comment. 8 Life Sciences Intellectual Property Review Volume 2, Issue 1
www.lifesciencesipreview
www.worldipreview.com
XPIXEL /
SHUTTERSTOCK.COM
MARTAN /
SHUTTERSTOCK.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44